Claire Morgan

Summary

Publications

  1. pmc Detection of p53 mutations in precancerous gastric tissue
    C Morgan
    Human Molecular Pathology Group, Swansea Clinical School, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK
    Br J Cancer 89:1314-9. 2003
  2. ncbi request reprint The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
    Claire Morgan
    Human Cancer Studies Group, School of Medicine, Swansea University, UK
    Acta Oncol 46:669-77. 2007
  3. doi request reprint Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?
    Claire Morgan
    Human Cancer Studies Group, Institute of Life Sciences, Swansea University, Singleton Park, UK
    Acta Oncol 48:882-9. 2009
  4. pmc Quantum dots for multiplexed detection and characterisation of prostate cancer cells using a scanning near-field optical microscope
    Kelly Ann D Walker
    College of Engineering, Multidisciplinary Nanotechnology Centre, Swansea University, Singleton Park, Swansea, United Kingdom
    PLoS ONE 7:e31592. 2012
  5. doi request reprint Metronomic administration of ibandronate and its anti-angiogenic effects in vitro
    Claire Morgan
    Human Cancer Studies Group, Institute of Life Sciences, Swansea University, Singleton Park, SA2 8PP, UK
    Microvasc Res 78:453-8. 2009
  6. ncbi request reprint The detection of mutations induced in vitro in the human p53 gene by hydrogen peroxide with the restriction site mutation (RSM) assay
    G J Jenkins
    Human Molecular Pathology Group, Swansea Clinical School, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK
    Mutat Res 498:135-44. 2001
  7. ncbi request reprint In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line
    Claire Morgan
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK
    Am J Gastroenterol 99:218-24. 2004
  8. ncbi request reprint iMARS--mutation analysis reporting software: an analysis of spontaneous cII mutation spectra
    Claire Morgan
    South West Wales Cancer Institute, Singleton Hospital, Swansea SA2 8QA, UK
    Mutat Res 603:15-26. 2006
  9. doi request reprint Clinical course of kidney transplant patients with acute rejection and BK virus replication following Campath therapy
    Liise K Kayler
    Department of Pathology, the Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Clin Transplant 22:348-53. 2008

Detail Information

Publications9

  1. pmc Detection of p53 mutations in precancerous gastric tissue
    C Morgan
    Human Molecular Pathology Group, Swansea Clinical School, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK
    Br J Cancer 89:1314-9. 2003
    ..pylori-positive and -negative groups. However, a small subpopulation of the H. pylori-negative patients had much higher levels of free radicals. This suggests a more prominent role for other factors in ROS production...
  2. ncbi request reprint The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
    Claire Morgan
    Human Cancer Studies Group, School of Medicine, Swansea University, UK
    Acta Oncol 46:669-77. 2007
    ....
  3. doi request reprint Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?
    Claire Morgan
    Human Cancer Studies Group, Institute of Life Sciences, Swansea University, Singleton Park, UK
    Acta Oncol 48:882-9. 2009
    ..One possibility could be ibandronate which is also a potent third generation, nitrogen-containing bisphosphonate and is an attractive choice for some patients due to the fact it is available in both intravenous and oral preparations...
  4. pmc Quantum dots for multiplexed detection and characterisation of prostate cancer cells using a scanning near-field optical microscope
    Kelly Ann D Walker
    College of Engineering, Multidisciplinary Nanotechnology Centre, Swansea University, Singleton Park, Swansea, United Kingdom
    PLoS ONE 7:e31592. 2012
    ....
  5. doi request reprint Metronomic administration of ibandronate and its anti-angiogenic effects in vitro
    Claire Morgan
    Human Cancer Studies Group, Institute of Life Sciences, Swansea University, Singleton Park, SA2 8PP, UK
    Microvasc Res 78:453-8. 2009
    ..They have been shown to inhibit proliferation, induce apoptosis and decrease capillary-like tube formation, but often the in vitro concentrations and dosing schedules used do not reflect drug pharmacokinetics or clinical dosing regimens...
  6. ncbi request reprint The detection of mutations induced in vitro in the human p53 gene by hydrogen peroxide with the restriction site mutation (RSM) assay
    G J Jenkins
    Human Molecular Pathology Group, Swansea Clinical School, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK
    Mutat Res 498:135-44. 2001
    ..Hence, this methodology may allow the detection of early p53 mutations in pre-malignant tissues...
  7. ncbi request reprint In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line
    Claire Morgan
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK
    Am J Gastroenterol 99:218-24. 2004
    ..The mechanisms underlying the hyperproliferative response are not well elucidated but may include alterations in Na(+)-H+ exchanger activity and MAPK signaling pathways...
  8. ncbi request reprint iMARS--mutation analysis reporting software: an analysis of spontaneous cII mutation spectra
    Claire Morgan
    South West Wales Cancer Institute, Singleton Hospital, Swansea SA2 8QA, UK
    Mutat Res 603:15-26. 2006
    ....
  9. doi request reprint Clinical course of kidney transplant patients with acute rejection and BK virus replication following Campath therapy
    Liise K Kayler
    Department of Pathology, the Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Clin Transplant 22:348-53. 2008
    ..Kidney transplant recipients with active BK virus (BKV) replication are generally treated with reduction in immunosuppression to allow a successful immune response against the virus...